US Bancorp DE grew its stake in Repligen Co. (NASDAQ:RGEN) by 14.1% in the 2nd quarter, HoldingsChannel reports. The institutional investor owned 3,522 shares of the biotechnology company’s stock after buying an additional 435 shares during the period. US Bancorp DE’s holdings in Repligen were worth $302,000 at the end of the most recent quarter.
Several other hedge funds also recently modified their holdings of the company. Royce & Associates LP lifted its stake in shares of Repligen by 40.6% in the first quarter. Royce & Associates LP now owns 502 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 145 shares during the period. Advisors Preferred LLC acquired a new position in shares of Repligen in the 2nd quarter worth approximately $39,000. C M Bidwell & Associates Ltd. acquired a new position in shares of Repligen in the 2nd quarter worth approximately $84,000. Ropes Wealth Advisors LLC bought a new stake in shares of Repligen in the 2nd quarter valued at $116,000. Finally, Regentatlantic Capital LLC bought a new stake in shares of Repligen in the 2nd quarter valued at $207,000. 86.51% of the stock is owned by institutional investors.
Shares of RGEN stock traded down $2.15 during trading hours on Tuesday, hitting $74.54. 219,021 shares of the company were exchanged, compared to its average volume of 1,063,961. The firm has a market cap of $3.95 billion, a P/E ratio of 102.11, a P/E/G ratio of 4.50 and a beta of 1.16. Repligen Co. has a fifty-two week low of $48.26 and a fifty-two week high of $99.25. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.88 and a current ratio of 2.25. The company has a 50 day simple moving average of $86.85 and a two-hundred day simple moving average of $76.27.
In other Repligen news, CEO Anthony Hunt sold 3,600 shares of Repligen stock in a transaction on Thursday, September 19th. The shares were sold at an average price of $82.89, for a total value of $298,404.00. Following the completion of the sale, the chief executive officer now directly owns 223,013 shares of the company’s stock, valued at $18,485,547.57. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 1.70% of the company’s stock.
RGEN has been the subject of a number of analyst reports. Zacks Investment Research downgraded shares of Repligen from a “buy” rating to a “hold” rating in a research note on Wednesday, August 7th. First Analysis upped their price target on shares of Repligen from $95.00 to $107.00 and gave the company an “outperform” rating in a research report on Wednesday, August 28th. HC Wainwright reiterated a “buy” rating and set a $110.00 price target on shares of Repligen in a report on Monday, August 12th. BidaskClub lowered Repligen from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, September 11th. Finally, ValuEngine downgraded Repligen from a “strong-buy” rating to a “buy” rating in a research note on Thursday, August 1st. One equities research analyst has rated the stock with a hold rating and ten have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $101.17.
Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.
Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Co. (NASDAQ:RGEN).
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.